Toxicity Testing Outsourcing Market (By Method: In Vitro, In Vivo; By GLP type; By End-use) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030.

The global toxicity testing outsourcing market is expected to register significant growth in the forecast period. The primary drivers of growth in the global toxicology testing outsourcing market are anticipated as increasing research and development on early toxicity detection, resistance to animal testing, and increasing research on pharmaceuticals. The market for outsourcing of toxicity testing services is anticipated to grow quickly due to the large number of research studies and drug development activities for COVID-19. As of May 2022, there were more than 1,100 compounds for COVID-19 in the development pipeline. It is projected that the large number of drug development programs will increase demand for toxicity testing services.

According to BioPlan Associates' 2022 19th Annual Report and Survey, biopharma companies are investing heavily, continuously focusing on acquiring better technologies, and exhibiting more optimism. Outsourcing of at least some tasks was reported by 86.9% of respondents from the biopharmaceutical industry in 2022, up from 82.6% in 2021 and 84.8% in 2020. According to the study, toxicology testing is the second most outsourced service, with 79.4% of respondents interested in outsourcing toxicology testing.

In vitro toxicology testing services are expected to grow at the fastest rate due to a push to "reduce, refine, or replace" in vivo experiments with alternatives that, ideally, are not animal-based, such as in silico computer models or in vitro cell-based systems that at least involve fewer animals, diminish or eliminate suffering or distress, and/or use less highly evolved species.

Only a small number of companies, mostly very large ones, still perform toxicology testing in-house. Most pharmaceutical and biopharmaceutical companies are now outsourcing toxicology testing to CROs or CDMOs. And to meet the increased demand for toxicology testing, CROs and CDMOs are expanding their existing capacity for toxicology testing services. For instance, in January 2020, Sinclair Research, a prominent provider of nonclinical contract research services in North America, announced the opening of its 20,000-square-foot laboratory expansion.

The key global industry players across the biosimilar contract manufacturing market include Lonza, Biocon, Catalent, Inc, Boehringer Ingelheim GmbH, Samsung BioLogics, AGC Biologics, and a few others.